VUEKENSE Trademark

Trademark Overview

On Friday, February 13, 2026, a trademark application was filed for VUEKENSE with the United States Patent and Trademark Office. The USPTO has given the VUEKENSE trademark a serial number of 99652376. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Friday, February 13, 2026. This trademark is owned by Belite Bio, Inc.. The VUEKENSE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of pharmaceutical and biopharmaceutical drugs and medicines for the treatment of degenerative retinal diseases; Research and development in the pharmaceutical, life sciences and biotechnology fields
vuekense

General Information

Serial Number99652376
Word MarkVUEKENSE
Filing DateFriday, February 13, 2026
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateFriday, February 13, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesResearch and development of pharmaceutical and biopharmaceutical drugs and medicines for the treatment of degenerative retinal diseases; Research and development in the pharmaceutical, life sciences and biotechnology fields

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, February 13, 2026
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBelite Bio, Inc.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressSan Diego, CA 92130

Trademark Events

Event DateEvent Description
Friday, February 13, 2026NEW APPLICATION ENTERED
Friday, February 13, 2026APPLICATION FILING RECEIPT MAILED

Related Keywords

vuekense research pharmaceutical development life sciences fields diseases biotechnology treatment biopharmaceutical